



VABYSMO[®]
faricimab injection 6 mg

From data to decision: Newest data in VABYSMO impacting clinical choices

EDUCATIONAL DINNER SYMPOSIUM | RANZCO 2025 PLATINUM PARTNER



YOU'RE INVITED!

DATE: 14th November 2025
TIME: 7:00 pm – 9:30 pm (AEDT)
VENUE: The Langham Melbourne



Scan QR code
to RSVP

This meeting is intended for
Ophthalmologists only.

Join local and international ophthalmology experts for an **educational dinner symposium at RANZCO 2025** as they share the latest clinical data for VABYSMO in nAMD, recently presented at EURETINA:

- **AVONELLE-X^{NEW}** – long-term outcomes with VABYSMO out to 4 years (LTE of the TENAYA/LUCERNE trials; post-hoc analysis)^{1,2}
- **SALWEEN^{NEW}** – outcomes with VABYSMO in patients with PCV out to 1 year (adapted from TENAYA/LUCERNE trials)^{1,3}

AGENDA

| TIME (AEDT) | SESSION |
|--------------|--|
| 7:00–7:30 pm | Arrival, registration and seating |
| 7:30–7:40 pm | Welcome and introduction |
| 7:40–8:00 pm | AVONELLE-X key outcomes and expert opinion |
| 8:00–8:20 pm | nAMD case study series and Q&A |
| 8:20–8:35 pm | An introduction to PCV |
| 8:35–8:55 pm | SALWEEN key outcomes and expert opinion |
| 8:55–9:15 pm | PCV case study series and Q&A |
| 9:15–9:25 pm | Summary and close |

**RSVP for the
opportunity
to submit a
real patient
case study for
expert review
and practical
guidance!**



VABYSMO[®]
faricimab injection 6 mg

MEET THE SPEAKERS



Prof Robyn Guymer (Chair)

MBBS, PhD, FRANZCO, FAHMS

CERA Deputy Director,
Head of Macular Research at
The University of Melbourne, VIC.



Dr Carl Danzig (USA)

MD

Director of Vitreoretinal Services
and Retina Clinical Research
at Rand Eye Institute, FL.



A/Prof Anna Tan (Singapore)

MBBS, M Med(Ophth),
FRCS(Ed), FAMS

Deputy Head and Senior Consultant
at Singapore National Eye Centre.



Dr David Sousa

MD, PhD, FRANZCO

Visiting Researcher in CERA's
Ophthalmic Neuroscience and
Retinal Gene Therapy Unit, VIC.



Dr Alex Tan

BMedSc(Hons), MBBS(Hons),
FRANZCO

Consultant Ophthalmologist
at Monash Health, VIC.



Dr James Wong

MBBS, MMed, FRANZCO

Medical Retinal Ophthalmologist
and Eye Surgeon at Sydney
Retina, NSW.

Please review the Product Information (PI) before prescribing, available at www.roche-australia.com/productinfo/vabysmo. VABYSMO ▼ PFS and vials are listed on the PBS for nAMD, DMO and RVO. Refer to PBS Schedule for full authority information.

Scan here to
access the
VABYSMO
Product
Information



▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

nAMD, neovascular (wet) age-related macular degeneration; PCV, polypoidal choroidal vasculopathy.

References: 1. Heier JS *et al. Lancet* 2022;399(10326):729–740. 2. Sheth V *et al.* Four-Year Outcomes of Faricimab in nAMD: Safety and Efficacy Results From the AVONELLE-X Long-Term Extension Trial. Slides presented at EURETINA 2025. 3. Lai TYY, *et al.* Presented at: 25th EURETINA Congress; 2025 Sep 4–7; Paris, France.

This promotional meeting is organised and funded by Roche Products Pty Limited and will involve the discussion of Roche medicines. Flights, accommodation and hospitality will be provided to healthcare professionals in line with the Medicines Australia Code of Conduct and Roche Code of Conduct. Prescribing information will be available at this meeting.

Roche product vigilance: To report a suspected side effect or product complaint associated with the use of a Roche product, visit www.medinfo.roche.com/australia or contact Roche Patient Safety at australia.safety@roche.com.

Further information is available on request from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney NSW 2000. Medical Enquiries: www.medinfo.roche.com/australia or 1800 233 950. ©Registered Trademark. VAB-005362-06. M-AU-00004668. Prepared Oct25.